Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Dose, Two-period, Crossover, Fed Bioequivalence Study of Darifenacin Extended Release Oral Formulation (Darisec(R) 15 mg) vs. Enablex(R) 15 mg in Healthy Volunteers.

NCT01227811 is registered in ClinicalTrials.gov with Center for Clinical Pharmacology Research Bdbeq S.A. as lead sponsor.

NCT NCT01227811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01227811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Dose, Two-period, Crossover, Fed Bioequivalence Study of Darifenacin Extended Release Oral Formulation (Darisec(R) 15 mg) vs. Enablex(R) 15 mg in Healthy Volunteers.
Lead sponsor
Center for Clinical Pharmacology Research Bdbeq S.A.
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2010
Completion date
March 31, 2011
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalency